By Sherri
Oslick —

About
Court
Report:  Each week we will report briefly on recently filed
biotech and pharma cases.

Pfizer Inc. et al. v. Watson Pharmaceuticals, Inc. et al.
0:10-cv-60674; filed April 29, 2010 in the Southern
District of Florida

• Plaintiffs:  Pfizer Inc.; Wyeth LLC; Wyeth
Pharmaceuticals Inc.
• Defendants:  Watson Pharmaceuticals, Inc.; Watson
Laboratories, Inc.-Florida; Watson Laboratories, Inc.; Watson Pharma, Inc.

Pfizer Inc. et al. v. Watson Pharmaceuticals Inc. et al.
1:10-cv-00357; filed April 28, 2010 in the District
Court of Delaware

• Plaintiffs:  Pfizer Inc.; Wyeth LLC; Wyeth
Pharmaceuticals, Inc.
• Defendants:  Watson Pharmaceuticals Inc.; Watson
Laboratories Inc. – Florida; Watson Laboratories Inc.; Watson Pharma Inc.;
Ranbaxy Laboratories Ltd.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy Inc.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent No. 5,100,899 ("Methods of Inhibiting Transplant Rejection in Mammals
Using Rapamycin and Derivatives and Prodrugs Thereof," issued March 31, 1992)
following a Paragraph IV certification as part of Watson's filing of an ANDA to
manufacture a generic version of Pfizer's Rapamune® (sirolimus, used for the
prophylaxis of organ rejection in patients aged 13 years or older receiving
renal transplants).  View the
Delaware complaint here.

Abbott Laboratories et al. v. Watson Laboratories, Inc.-Florida
et al.
0:10-cv-60677; filed April 29, 2010 in the Southern
District of Florida

• Plaintiffs:  Abbott Laboratories; Fournier
Laboratories Ireland Ltd.
• Defendants:  Watson Laboratories, Inc.-Florida;
Watson Pharma, Inc.; Watson Pharmaceuticals, Inc.

Abbott Laboratories et al. v. Watson Laboratories, Inc.-Florida
et al.
2:10-cv-02139; filed April 27, 2010 in the District
Court of New Jersey

• Plaintiffs:  Abbott Laboratories; Fournier
Laboratories Ireland Ltd.
• Defendants:  Watson Laboratories, Inc.-Florida;
Watson Pharma, Inc.; Watson Pharmaceuticals, Inc.

Abbott Laboratories et al. v. Mylan Pharmaceuticals Inc. et al.
2:10-cv-02073; filed April 23, 2010 in the District
Court of New Jersey

• Plaintiffs:  Abbott Laboratories; Fournier
Laboratories Ireland Ltd.
• Defendants:  Mylan Pharmaceuticals Inc.;
Mylan, Inc.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent No. 7,259,186 ("Salts of Fenofibric Acid and Pharmaceutical
Formulations Thereof," issued August 21, 2007) following a Paragraph IV
certification as part of defendants' filing of an ANDA to manufacture a generic
version of Abbott's Trilipix® (choline fenofibrate delayed release, used to
treat increased triglyceride levels).  View the Florida Watson complaint here.

Shionogi Pharma Inc. et al. v. Impax Laboratories Inc.
1:10-cv-00358; filed April 28, 2010 in the District
Court of Delaware

• Plaintiffs:  Shionogi Pharma Inc.; LifeCycle
Pharma AS
• Defendant:  Impax Laboratories Inc.

Infringement of U.S. Patent No. 7,658,944 ("Solid
Dosage Form Comprising a Fibrate," issued February 9, 2010) following a
Paragraph IV certification as part of Impax's filing of an ANDA to manufacture
a generic version of Shionogi's Fenoglide® (fenofibrate, used to treat
hyperlipidemia, mixed dyslipidemia, or hypertriglyceridemia).  View the complaint here.

Medicis Pharmaceutical Corp. v. Taro Pharmaceutical USA
Inc. et al
1:10-cv-00359; filed April 28, 2010 in the District
Court of Delaware

• Plaintiff:  Medicis Pharmaceutical Corp.
• Defendants:  Taro Pharmaceutical USA Inc.; Taro
Pharmaceutical Industries Ltd.

Medicis Pharmaceutical Corp. v. Taro Pharmaceutical
U.S.A., Inc. et al.
1:10-cv-03549; filed April 28, 2010 in the Southern
District of New York

• Plaintiff:  Medicis Pharmaceutical Corp.
• Defendants:  Taro Pharmaceutical U.S.A., Inc.;
Taro Pharmaceutical Industries, Ltd.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent Nos. 6,765,001 ("Compositions and Methods for Enhancing
Corticosteroid Delivery," issued July 20, 2004), 7,220,424 (same title,
issued May 22, 2007), and 7,217,422 (same title, issued May 15, 2007) following
a Paragraph IV certification as part of Taro's filing of an ANDA to manufacture
a generic version of plaintiff's Vanos® (fluocinonide cream, used to relieve
inflammation and itching caused by certain skin conditions that respond to
corticosteroids).  View the
Delaware complaint here.

Celgene Corp. v. Cyclacel Pharmaceuticals Inc.
1:10-cv-00348; filed April 27, 2010 in the District
Court of Delaware

Declaratory judgment of non-infringement and
invalidity of U.S. Patent Nos. 6,403,555 ("Depsipeptide and Congeners Thereof
for Use as Immunosuppressants," issued June 11, 2002), 6,548,479 ("Therapeutic
Uses of Depsipeptide and Congeners Thereof," issued April 15, 2003), 6,828,302
("same title, issued December 7, 2004), and 7,041,639 ("Depsipeptide and
Congeners Thereof for Use as Immunosuppressants," issued May 9, 2006) based on
Celgene's manufacture and sale of its Istodax® product (romidepsin, used to
treat cutaneous T-cell lymphoma).  View the complaint here.

AstraZeneca Pharmaceuticals LP et al. v. Apotex Corp.
1:10-cv-00338; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendant:  Apotex Corp.

AstraZeneca Pharmaceuticals LP et al. v. Aurobindo Pharma
Ltd. et al.
1:10-cv-00339; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendants:  Aurobindo Pharma Ltd.; Aurobindo
Pharma USA Inc.

AstraZeneca Pharmaceuticals LP et al. v. Cobalt Pharmaceuticals
Inc. et al.
1:10-cv-00340; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendants:  Cobalt Pharmaceuticals Inc.; Cobalt
Laboratories Inc.

AstraZeneca Pharmaceuticals LP et al. v. Cobalt Pharmaceuticals
Inc. et al.
1:10-cv-00340; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendants:  Cobalt Pharmaceuticals Inc.; Cobalt
Laboratories Inc.

AstraZeneca Pharmaceuticals LP et al. v. Glenmark Generics Inc.
USA
1:10-cv-00341; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendant:  Glenmark Generics Inc. USA

AstraZeneca Pharmaceuticals LP et al. v. Mylan Pharmaceuticals
Inc.
1:10-cv-00342; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendant:  Mylan Pharmaceuticals Inc.

AstraZeneca Pharmaceuticals LP et al. v. Par Pharmaceutical Inc.
1:10-cv-00343; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs: AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendant: Par Pharmaceutical Inc.

AstraZeneca Pharmaceuticals LP et al. v. Sandoz Inc.
1:10-cv-00344; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendant:  Sandoz Inc.

AstraZeneca Pharmaceuticals LP et al. v. Sun Pharmaceutical
Industries Ltd. et al.
1:10-cv-00345; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital,
Inc.
• Defendants:  Sun Pharmaceutical Industries Ltd.;
Sun Pharmaceutical Industries Inc.; Caraco Pharmaceutical Laboratories
Ltd.

AstraZeneca Pharmaceuticals LP et al. v. Teva Pharamceuticals
USA, Inc.
1:10-cv-00346; filed April 26, 2010 in the District
Court of Delaware

• Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
Pharmaceuticals Inc.; AstraZeneca AB; The Brigham and Women's Hospital, Inc.
• Defendant:  Teva Pharamceuticals USA, Inc.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent Nos. 6,858,618 ("Use of Rosuvastatin (ZD-4522) in the Treatment of
Heterozygous Familial Hypercholesterolemia," issued February 22, 2005) and
7,030,152 ("Systematic Inflammatory Markers as Diagnostic Tools in the
Prevention of Atherosclerotic Diseases and as Tools to Aid in the Selection of
Agents to be Used for the Prevention and Treatment of Atherosclerotic Disease,"
issued April 18, 2006) following a Paragraph IV certification as part of
defendants' filing of an amended ANDA to manufacture a generic version of
AstraZeneca's Crestor® (rosuvastatin calcium, used to treat high
cholesterol).  View the Apotex
complaint here.

Teva Women's Health, Inc. v. Watson Laboratories, Inc. et al.
2:10-cv-02061; filed April 23, 2010 in the District
Court of New Jersey

• Plaintiff:  Teva Women's Health, Inc.
• Defendants:  Watson Laboratories, Inc.; Watson
Pharmaceuticals, Inc.

Infringement of U.S. Patent No. 5,908,638
("Pharmaceutical Compositions of Conjugated Estrogens and Methods for
Their Use," issued June 1, 1999) following a Paragraph IV certification as
part of Watson's filing of an ANDA to manufacture a generic version of Teva
Women's Health's Cenestin® (synthetic conjugated estrogens, used to treat
peri-menopausal, menopausal, and post-menopausal disorders).  View the complaint here.

Shire LLC et al v. Teva Pharmaceuticals USA Inc. et al.
1:10-cv-00329; filed April 22, 2010 in the District
Court of Delaware

• Plaintiffs:  Shire LLC; Supernus
Pharmaceuticals Inc.
• Defendants:  Teva Pharmaceuticals USA Inc.; Teva
Pharmaceutical Industries Ltd.

Infringement of U.S. Patent Nos. 6,287,599
("Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent
Dissolution Profiles," issued September 11, 2001) and 6,811,794 (same title,
issued November 2, 2004) based on Teva's filing of an ANDA to manufacture a
generic version of Shire's Intuniv (guanfacine, used to treat attention-deficit
hyperactivity disorder).  View the
complaint here.

Wyeth LLC v. Aurobindo Pharma Ltd. et al.
3:10-cv-02084; filed April 22, 2010 in the District
Court of New Jersey

• Plaintiffs:  Wyeth LLC
• Defendants:  Aurobindo Pharma Ltd.; Aurobindo
Pharma USA Inc.

Infringement of U.S. Patent Nos. 6,274,171
("Extended release formulation of venlafaxine hydrochloride," issued
August 14, 2001), 6,403,120 (same title, issued June 11, 2002), and 6,419,958
(same title, issued July 16, 2002) following a Paragraph IV certification as
part of Aurobindo's filing of an ANDA to manufacture a generic version of
Wyeth's EFFEXOR XR® (venlafaxine hydrochloride, extended release, used to treat
depression).  View the complaint here.